Jacinda Sampson, MD
Neuromuscular Medicine · Stanford, CANPI 1427000710
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,216 of the $3,770 with a category attached, or 85.3%. Biogen accounts for 77.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $2,960 and has fallen 84.0% since, to $473 in 2025.
Across 11 payments — averaging $342.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$3K
- Vertex$458
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$143
- Genentech, Inc.$141
- Novartis$92
- UCB, Inc.$15
Across 23 payments — averaging $16,241 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$150K
- Ionis Pharmaceuticals, Inc.$123K
- Vertex$88K
- Pfizer$13K
What the payments were for
- Consulting fees$3,21685%
- Speaking & faculty fees$602%
- Food & beverage$47913%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 3 | $2,923 |
| Vertex | 1 | $458 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 4 | $143 |
| Genentech, Inc. | 1 | $141 |
| Novartis | 1 | $92 |
| UCB, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,770 in reported general payments places this provider in the 60th percentile of 44 neuromuscular medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 57 | $771,930 |
| Riluzole | 40 | $5,191 |
| Atovaquone | 16 | $1,797 |
| Baclofen | 33 | $1,417 |
| Pyridostigmine Bromide | 12 | $1,055 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 27 | $784 |
| Gabapentin | 30 | $748 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 25 | $454 |
| Tizanidine Hcl | 11 | $268 |
| Prednisone | 15 | $137 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in Stanford
- John DayStanford$294K
- Yuen SoStanford$7K
- Sarada SakamuriStanford$404
- Kathie LinStanford$214
- Maxwell GreeneStanford$111
- Kenneth LeungStanford$15
- Samir MacwanRancho Mirage$983K
- Ali HabibOrange$445K
- Tahseen MozaffarOrange$428K
- Jeffrey RosenfeldFresno$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.